CLINICAL USE


Prophylactic treatment of vascular headaches including migraine

DOSE IN NORMAL RENAL FUNCTION

1.5 mg at night or 500 mcg 3 times a day adjusted according to responseMaximum single dose: 3 mgMaximum daily dose: 4.5 mg

PHARMACOKINETICS

  • Molecular weight &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :429.5 (as malate)
  • %Protein binding &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :>90
  • %Excreted unchanged in urine &nbsp &nbsp : <1 (55% as metabolites)

  • Volume of distribution (L/kg) &nbsp &nbsp &nbsp :6–8

  • half-life – normal/ESRD (hrs)&nbsp &nbsp &nbsp :1 (metabolite 23 hours)

    DOSE IN RENAL IMPAIRMENT

    GFR (mL/MIN)

  • 20 to 50 &nbsp &nbsp : Dose as in normal renal function
  • 10 to 20 &nbsp &nbsp : Dose as in normal renal function
  • <10 &nbsp &nbsp &nbsp &nbsp &nbsp : Dose reduction may be required. Monitor for drowsiness

    DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES

  • CAPD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp:Unlikely to be dialysed. Dose as in GFR <10 mL/min
  • HD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :Unlikely to be dialysed. Dose as in GFR <10 mL/min
  • HDF/high flux &nbsp :Unknown dialysability. Dose as in GFR <10 mL/min
  • CAV/VVHD &nbsp &nbsp &nbsp:Unlikely to be dialysed. Dose as in normal renal function

    IMPORTANT DRUG INTERACTIONS

    Potentially hazardous interactions with other drugsAdrenergic neurone blockers: pizotifen antagonises hypotensive effect

    ADMINISTRATION

    Reconstition

    –

    Route

    Oral

    Rate of Administration

    –

    Comments

    –

    OTHER INFORMATION

    Use with caution in people with a predisposition for urinary retention or closed angle glaucomaPizotifen has appetite stimulating properties.

    Tags:

    • Related News

    ffddfd

    Hyperlipidemia